About this trial
This prospective, multicenter, open-label, randomized-controlled trial compares two treatment strategies in high-risk ischemic cardiomyopathy (ICM) patients referred for primary ICD implantation. Participants will be randomized to receive either prophylactic VT ablation within three months of ICD implantation or continued medical management. The primary objective is to assess the efficacy of preventive VT ablation versus medical management in reducing VT arrhythmia burden.
Eligibility criteria
Qualifiers
Age ≥ 18 years (no upper age limit)
Willing and able to provide informed consent
Candidate for a primary prevention ICD/CRT-D per ESC guidelines17
Ischemic cardiomyopathy (ICM) with left ventricular ejection fraction (LVEF) ≤ 35%
Disqualifiers
Existing ICD or CRT-D
History of sustained VT or VF
Chronic renal failure requiring hemodialysis
Coronary revascularization within the past 3 months
Trial design
Treatments tested in this trial
- Prophylactic Catheter-based VT Ablation